(Q33856597)

English

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

9

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

5

object named as

Zeev Estrov

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

4

object named as

Tapan Kadia

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

2

object named as

Elias Jabbour

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Gautam Borthakur

3

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

8

object named as

Sherry Pierce

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Guillermo Garcia-Manero

10

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Sophie Dimicoli

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Hui Yang

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Mary Kelly

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

10 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

87

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

127-129

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4085038

5 July 2018

Hypomethylating agents and other novel strategies in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4085038

5 July 2018

Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4085038

5 July 2018

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4085038

5 July 2018

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4085038

5 July 2018

Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4085038

5 July 2018

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4085038

5 July 2018

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4085038

5 July 2018

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4085038

29 October 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22072492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/22072492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/AJH.22198

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33856597&oldid=1987770431"